FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Almstead Neil Gregory   2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Research Pharma Ops & Tech (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT 3. Date of Earliest Transaction (Month/Day/Year) 06/19/2018 (Street) SOUTH PLAINFIELD, NJ 07080 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/19/2018   M(1)   20,000 A $ 10.85 37,154 D   Common Stock 06/19/2018   S(1)   8,000 D $ 48.09 (2) 29,154 D   Common Stock 06/19/2018   S(1)   12,000 D $ 48.46 (3) 17,154 D   Common Stock               5,125 I By spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right To Buy)	$ 10.85	06/19/2018		M(1)			20,000	(4)	05/15/2023	Common Stock	20,000	$ 10.85	46,898	D
Stock Option (Right To Buy)	$ 451.2							(4)	05/15/2019	Common Stock	200		200	D
Stock Option (Right To Buy)	$ 1,149.6							(4)	02/02/2020	Common Stock	200		200	D
Stock Option (Right To Buy)	$ 490.8							(4)	04/27/2021	Common Stock	216		216	D
Stock Option (Right To Buy)	$ 218.4							(4)	01/10/2022	Common Stock	166		166	D
Stock Option (Right To Buy)	$ 10.85							(4)	05/15/2023	Common Stock	3,102		3,102	D
Stock Option (Right To Buy)	$ 27.05							(4)	01/27/2024	Common Stock	40,000		40,000	D
Stock Option (Right To Buy)	$ 51							(5)	01/01/2025	Common Stock	69,550		69,550	D
Stock Option (Right To Buy)	$ 30.86							(6)	01/03/2026	Common Stock	55,000		55,000	D
Stock Option (Right To Buy)	$ 11.23							(7)	01/02/2027	Common Stock	35,000		35,000	D
Stock Option (Right To Buy)	$ 18.01							(8)	01/02/2028	Common Stock	70,000		70,000	D
Stock Option (Right To Buy)	$ 508.8							(4)	10/07/2019	Common Stock	12		12	I	By spouse
Stock Option (Right To Buy)	$ 1,149.6							(4)	02/02/2020	Common Stock	1		1	I	By spouse
Stock Option (Right To Buy)	$ 490.8							(4)	04/27/2021	Common Stock	7		7	I	By spouse
Stock Option (Right To Buy)	$ 218.4							(4)	01/10/2022	Common Stock	7		7	I	By spouse
Stock Option (Right To Buy)	$ 27.05							(4)	01/27/2024	Common Stock	1,300		1,300	I	By spouse
Stock Option (Right To Buy)	$ 51							(5)	01/01/2025	Common Stock	2,060		2,060	I	By spouse

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Almstead Neil Gregory C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080			EVP Research Pharma Ops & Tech

Signatures

/s/ Avraham S. Adler, attorney-in-fact		06/21/2018
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
(2)	This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
(3)	This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
(4)	Currently exercisable.
(5)	This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
(6)	This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
(7)	This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
(8)	This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.